Latest Legal Dispute News

Nimy Resources has been hit with a $3.75 million legal claim from Lind Global Fund alleging breach of a placement agreement. The mining company disputes the claim and plans to defend the case in court.

FAR Limited reports robust production from Senegal’s Sangomar field and receives a provisional $11.5 million contingent payment, while addressing a $6 million indemnity claim from Woodside Energy.

Integral Diagnostics has been served with a legal claim from vendors disputing the earn out valuation of its Imaging Queensland acquisition, despite an independent expert's prior valuation. The company plans to defend the claim, which could have financial and reputational implications.

Bastion Minerals and former advisor GTT Ventures have resolved their legal dispute, leading to the withdrawal of a writ that had cast uncertainty over the company.

Triton Minerals updates investors on ongoing legal disputes over its Mozambique graphite project SSAP, rejecting a recent counterproposal and enacting strict cost-cutting measures to preserve cash.

Jatcorp anticipates a significant net loss for FY2025 driven by halted sales in China and legal disputes, yet remains cautiously optimistic about growth prospects in FY2026.

AMP Limited is set to defend itself against a new class action alleging inflated life insurance premiums and a separate dispute over a major property sale, signaling potential challenges ahead for the financial services giant.

EML Payments has reached an in-principle agreement to settle a $37.36 million shareholder class action related to its 2020 acquisition, allowing the company to focus on its strategic growth plans.

Dexus reports a slight 0.4% increase in portfolio valuations driven by rental growth, alongside an 18-cent estimated distribution. Meanwhile, legal proceedings involving its APAC stake face delays, clouding future outcomes.

RLF AgTech has resolved a legal dispute over a consultancy agreement, clearing the way for renewed focus on expanding its crop nutrition business domestically and internationally.

Mayne Pharma shareholders have overwhelmingly approved a scheme for Cosette Pharmaceuticals to acquire the company, setting the stage for a pivotal court hearing later this year.

Mayne Pharma shareholders have overwhelmingly approved the scheme of arrangement for Cosette Pharmaceuticals to acquire the company at $7.40 per share, despite ongoing legal challenges and regulatory approvals still pending.